SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-151729
Filing Date
2021-05-05
Accepted
2021-05-05 16:14:05
Documents
14
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d342613d8k.htm   iXBRL 8-K 25307
2 EX-99.1 d342613dex991.htm EX-99.1 48179
6 GRAPHIC g342613dsp4.jpg GRAPHIC 3742
  Complete submission text file 0001193125-21-151729.txt   215431

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gthx-20210505.xsd EX-101.SCH 3087
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gthx-20210505_lab.xml EX-101.LAB 18907
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gthx-20210505_pre.xml EX-101.PRE 11874
7 EXTRACTED XBRL INSTANCE DOCUMENT d342613d8k_htm.xml XML 3478
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 21893414
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences